Business Context and Reporting Period
Inhibikase Therapeutics, Inc. (IKT) is a clinical-stage pharmaceutical company focused on developing protein kinase inhibitor therapeutics for Parkinson's disease (PD), Multiple System Atrophy (MSA), and other neurodegenerative disorders. The company's lead program, Risvodetinib (IkT-148009), targets PD and MSA. A secondary program, IkT-001Pro, is a prodrug of imatinib mesylate intended for Chronic Myelogenous Leukemia (CML) and Pulmonary Arterial Hypertension (PAH). This Form 10-Q covers the quarterly period ended June 30, 2024.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(4,959,608) | $(9,609,243) |
| Net Loss Per Share (Basic & Diluted) | $(0.66) | $(1.38) |
| Cash and Cash Equivalents | $3,086,455 (as of June 30, 2024) | |
| Marketable Securities | $4,853,559 (as of June 30, 2024) | |
| Working Capital | $4,898,258 (as of June 30, 2024) | |
| Accumulated Deficit | $(76,509,968) (as of June 30, 2024) | |
| Net Cash Used in Operating Activities | $(8,921,392) (Six Months) |
Material Changes vs. Prior Period
- Revenue: Grant revenue was $0 for the three and six months ended June 30, 2024, compared to $116,410 and $180,931, respectively, in the prior year periods. The company did not submit current clinical trials for grant funding.
- Research and Development (R&D): R&D expenses decreased by 32.2% ($1.46 million) for the quarter and 21.1% ($1.56 million) for the six months compared to the prior year. This reduction was primarily driven by the completion of the IkT-001Pro dose-finding study in 2023, partially offset by increased spending on the Risvodetinib (IkT-148009) program.
- Selling, General and Administrative (SG&A): SG&A expenses increased by 10.7% ($0.19 million) for the quarter and 8.0% ($0.30 million) for the six months, driven mainly by higher legal and consulting fees.
- Interest Income: Interest income decreased significantly (78.6% for the quarter, 66.2% for the six months) due to reduced interest earned on U.S. Treasuries and money market instruments.
- Capital Raises: The company raised approximately $3.2 million in net proceeds in May 2024 through a registered direct offering and concurrent private placement. Additionally, $820,509 was raised via an At-The-Market (ATM) offering.
Guidance, Outlook, Risks, and Contingencies
- Going Concern: The company has incurred recurring losses and an accumulated deficit of $76.5 million. Management estimates current working capital is sufficient to fund operations only into December 2024. These conditions raise substantial doubt about the company's ability to continue as a going concern for one year following the report date. Future operations depend on raising additional capital.
- Clinical Progress: The Phase 2 "201 trial" for Risvodetinib in Parkinson's disease was fully enrolled in June 2024, with results expected in Q4 2024. The company plans to extend the trial by up to 12 months subject to financing. For IkT-001Pro, the FDA indicated the 505(b)(2) pathway is appropriate for CML approval, and an IND for PAH was filed in August 2024.
- Legal Proceedings: In April 2024, Pivot Holding LLC demanded arbitration alleging breach of contract regarding milestone payments, seeking $1.625 million plus interest. The company disputes these claims and has filed a counterclaim for over $900,000 in damages. Mediation is scheduled for September 6, 2024.
- Internal Controls: The company identified a material weakness in internal controls over financial reporting related to the calculation of net loss per share (specifically the exclusion of pre-funded warrants). Prior period EPS figures have been restated to correct this error.
Investor Verification Checklist
- Liquidity Runway: Verify the timeline for the next capital raise, as current cash reserves are projected to last only until December 2024.
- Legal Exposure: Monitor the outcome of the arbitration with Pivot Holding LLC regarding the $1.625 million claim and the company's counterclaim.
- Clinical Trial Extension: Confirm the funding status and regulatory approval for the proposed 12-month extension of the Risvodetinib Phase 2 trial.
- Internal Control Remediation: Review future filings to ensure the material weakness regarding EPS calculations has been fully remediated.
- Grant Revenue: Assess the likelihood of securing new government grants to offset operating losses, given the cessation of grant revenue in 2024.